| CAS NO: | 2248703-42-4 |
| 包装 | 价格(元) |
| 1mg | 电议 |
| 5mg | 电议 |
| 10mg | 电议 |
| Cas No. | 2248703-42-4 |
| Canonical SMILES | ClCC(N[C@@H](CO)[C@@H](CCCCCCCCCCCCCCC)O)=O |
| 分子式 | C20H40ClNO3 |
| 分子量 | 378 |
| 溶解度 | Chloroform: soluble |
| 储存条件 | -20°C |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
| Shipping Condition | Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request |
| 产品描述 | SACLAC is an irreversible inhibitor of acid ceramidase (Ki= 97.1 nM) and a derivative of the acid ceramidase inhibitor SABRAC .1It decreases levels of sphingosine-1-phosphate (S1P) and increases total ceramide levels in OCI-AML-2 acute myeloid leukemia (AML) cells when used at a concentration of 2.5 µM.2SACLAC (10 and 20 µM) induces apoptosis in primary AML cells. It reduces leukemic burden in MV4-11 and U937 AML mouse xenograft models when administered at a dose of 5 mg/kg. 1.OrdÓÑez, Y.F., Abad, J.L., Aseeri, M., et al.Activity-based imaging of acid ceramidase in living cellsJ. Am. Chem. Soc.141(19)7736-7742(2019) 2.Pearson, J.M., Tan, S.-F., Sharma, A., et al.Ceramide analogue SACLAC modulates sphingolipid levels and MCL-1 splicing to induce apoptosis in acute myeloid leukemiaMol. Cancer Res.18(3)352-363(2020) |
m.cnreagent.com